Mesoblast limited (NASDAQ:MESO) Given Consensus Rating of Buy by Brokerages – Redmond Register

Mesoblast limited (NASDAQ:MESO) has received an average rating of Buy from the nine brokerages that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $13.83.

Several brokerages recently commented on MESO. Zacks Investment Research downgraded Mesoblast from a buy rating to a hold rating in a report on Tuesday, March 3rd. Maxim Group reiterated a buy rating and set a $16.00 target price on shares of Mesoblast in a report on Friday, February 28th. HC Wainwright reiterated a buy rating and set a $14.00 target price on shares of Mesoblast in a report on Thursday, February 6th. TheStreet upgraded Mesoblast from a d rating to a c- rating in a report on Monday, December 2nd. Finally, Dawson James began coverage on Mesoblast in a report on Thursday, December 19th. They set a buy rating and a $14.00 target price on the stock.

Several large investors have recently made changes to their positions in MESO. M&G Investment Management Ltd. purchased a new stake in shares of Mesoblast during the 4th quarter valued at about $10,440,000. Tobias Financial Advisors Inc. purchased a new stake in Mesoblast during the 4th quarter worth approximately $191,000. Penbrook Management LLC increased its holdings in Mesoblast by 3.9% during the 4th quarter. Penbrook Management LLC now owns 232,100 shares of the companys stock worth $1,711,000 after purchasing an additional 8,800 shares during the last quarter. Finally, Wilbanks Smith & Thomas Asset Management LLC increased its holdings in Mesoblast by 6.0% during the 4th quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 25,025 shares of the companys stock worth $184,000 after purchasing an additional 1,425 shares during the last quarter. Institutional investors and hedge funds own 2.07% of the companys stock.

Mesoblast (NASDAQ:MESO) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The firm had revenue of $2.21 million during the quarter, compared to analyst estimates of $6.54 million. Mesoblast had a negative net margin of 337.18% and a negative return on equity of 15.48%. On average, equities research analysts expect that Mesoblast will post -0.55 EPS for the current fiscal year.

About Mesoblast

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Stem Cell Clinic

Stem Cell News

Mesoblast limited (NASDAQ:MESO) Given Consensus Rating of Buy by Brokerages – Redmond Register